Skip to main content
Premium Trial:

Request an Annual Quote

Aragen Bioscience Inks License with Cevec

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Aragen Bioscience has licensed the rights to use Cevec Pharmaceuticals' CAP-T protein production technology in its custom recombinant cell line offerings, CEVEC said today.

The license gives Aragen the rights to offer its research clients custom recombinant human cell lines that express biotherapeutic proteins and antibodies using the Cevec technology, which is based on CAP cells, a cell line used for stable protein production.

These non-tumor origin cell lines exhibit high protein expression, have been adapted to serum-free suspension culture, and they include human-like post-translational modifications.

"We believe that human cells will be a superior production system for a variety of complex proteins," Aragen Bioscience CEO Rick Srigley said in a statement. "Cevec's technology is a valuable addition to our existing expression portfolio and will enable our customers to pursue new directions for proteins that were difficult in the past or did not show satisfactory post-translational modifications."

Financial terms of the agreement were not released.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.